Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.62 |
| ▸ | BCL9 | O00512 | 1/20 | 0.61 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27882785 | 0.98 | MGLL (0.60) | MGLLBCL9CTNNB1HTR2AGAA | |
| SCHEMBL1958366 | 0.97 | MGLL (0.60) | MGLLBCL9CTNNB1HTR2AGAA | |
| SCHEMBL21433889 | 0.96 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AGAA | |
| SCHEMBL21777065 | 0.96 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AGAA | |
| SCHEMBL9846659 | 0.96 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AGAA | |
| SCHEMBL21433779 | 0.96 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AGAA | |
| SCHEMBL29830677 | 0.96 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AGAA | |
| SCHEMBL21433828 | 0.96 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AGAA | |
| SCHEMBL2234364 | 0.96 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AGAA | |
| SCHEMBL29398055 | 0.96 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | CONFO THERAPEUTICS N.V. (BE) | 2024-11-07 | — | — | US | disclosed |
| EP-4377307-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | Confo Therapeutics N.V. (BE) | 2024-06-05 | — | — | EP | disclosed |
| EP-3728216-B1 | PYRAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116640117-A | Triazole LPAR1 antagonists and uses thereof | 武汉人福创新药物研发中心有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023109878-A1 | TRIAZASPIRO LPAR1 ANTAGONIST AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109878-A1 | TRIAZASPIRO LPAR1 ANTAGONIST AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023006893-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | CONFO THERAPEUTICS N.V. (BE) | 2023-02-02 | — | — | WO | disclosed |
| US-11384067-B2 | Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-07-12 | — | — | US | disclosed |
| EP-4011875-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022100625-A1 | NITROGEN-SUBSTITUTED AMINOCARBONATE THIOPHENE COMPOUND AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-05-19 | — | — | WO | disclosed |
| US-20100016602-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016602-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2070536-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PHENYLAMIDINE DERIVATIVE AND METHOD OF USING THE PHARMACEUTICAL COMPOSITION IN COMBINATION WITH ANTIFUNGAL AGENT | Toyama Chemical Co., Ltd. (JP) | 2009-06-17 | — | — | EP | disclosed |
| EP-1967190-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007090733-A1 | NITROOXY DERIVATIVES SUITABLE AS ALPHA2 ADRENERGIC RECEPTOR AGONISTS | NICOX S.A. (FR) | 2007-08-16 | — | — | WO | disclosed |
| US-20070032405-A1 | Branched water-soluble polymers and their conjugates | NEOSE TECHNOLOGIES, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| CN-1062561-C | 7-halo-and 7 beta, 8 beta-methylene-paclitaxel, antitumor use and pharmaceutical composition containing the same | PHARMAIN & UPJOHN CO (US) | 2001-02-28 | — | — | CN | disclosed |
| CN-1261072-A | 7-halogenated and 7 beta, 8 beta-methylene-taxinol, its usage against cancers and medicinal compositions containing it | UPJOHN CO (US) | 2000-07-26 | — | — | CN | disclosed |
| WO-2000002864-A1 | PRECUSORS FOR PNA-MONOMERS | MARTENS JUERGEN (DE) | 2000-01-20 | — | — | WO | disclosed |
| CN-1095377-A | 7-halo-and 7 beta, 8 beta-methylene-paclitaxel, antitumor use and pharmaceutical composition containing the same | UPJOHN CO (US) | 1994-11-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | AGTR2, AGTR1, OPRL1 | MGLL 2395/4885BCL9 4720/4885CTNNB1 2820/4885 |
| US-20100016602-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | ERG28, DPM1, NAT1 | MGLL 3679/4885BCL9 2659/4885CTNNB1 4861/4885 |
| US-11384067-B2 | Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR4, LPAR5 | MGLL 1238/4885BCL9 2446/4885CTNNB1 1917/4885 |
| US-20070032405-A1 | Branched water-soluble polymers and their conjugates | SLC7A5, SLC43A1, SLC7A1 | MGLL 132/4885BCL9 1370/4885CTNNB1 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.